Read-Gene Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 24
Employees
  • Stock Symbol
  • RDG
Stock Symbol
  • Share Price
  • $0.95
  • (As of Friday Closing)

Read-Gene General Information

Description

Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Stock Exchange
WAR
Primary Office
  • Ul. Alabastrowa 8
  • Grzepnica, 72-003
  • Poland
+48 91 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Read-Gene Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.95 $0.83 $0.22 - $1.12 $11.2M 5.51K $0.05

Read-Gene Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 4,137 1,013 751 4,455
Revenue 1,676 1,658 1,972 1,270
EBITDA 599 427 668 53
Net Income 593 31 224 14
Total Assets 4,145 4,279 4,447 5,226
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Read-Gene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial